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Autoimmune thyroid diseases are common manifestations of hepatitis C infection, exacerbated by interferon-based treatment.
However, the occurrence and pattern of thyroid disease in the short/medium term following the completion of IFN-based therapy
is relatively unknown and there are very few previous reports regarding the speciﬁc spectrum of autoimmune thyroid disease that
may follow such therapy. We hereby report 3 cases which demonstrate the range of thyroid diseases that may occur following
interferon therapy. The hypothesis advanced is that in the pathogenesis of these conditions there must be both triggering and
sustaining mechanisms as thyroid diseases occur well outside the immediate eﬀect window of pegylated interferon. This paper
suggests the need to continue thyroid surveillance in IFN-treated HCV patients following the completion of therapy, perhaps for
the ﬁrst 6 months.
Copyright © 2009 H. A. Tran and G. E. M. Reeves. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.ClinicalCase Notes
1.1. Case 1. A 53-year-old man underwent combination
Ribavirin (RBV) and Interferon-α2β (IFN-α2β)f o rat o t a l
of 48 weeks because of his HCV genotype 1 and had
achieved sustained virological response (SVR). During this
time, he developed IFN-induced thyroiditis at 18 weeks
with the classical biphasic thyrotoxic phase followed by
hypothyroidism. The condition completely resolved by the
38th week, including normal thyrotropin (TSH), free tetra-
iodothyronine (fT4), and free tri-iodothyronine (fT3). Thy-
roid hormone levels were followed monthly throughout the
duration of treatment. There was no family or prior history
of thyroid disease and antiviral therapy was continued
despite his thyroid condition. He represented with general
lethargy and weight loss of 3kg two months after the
completion of treatment for his chronic hepatitis C (HCV)
infection. Clinical examination at this time showed sinus
tachycardia at 101 beats per minute (bpm), blood pressure
(BP) of 120/80 with no postural hypotension. There were
peripheral stigmata of thyrotoxicosis but no signs of Graves’
ophthalmopathy or dermopathy. No goitre was present.
His TSH was undetectable (reference range (RR), 0.4–
4.0IU/L), fT4 19.8 (RR, 10.5–24.5pmol/L) and fT3 8.9 (RR,
3.5–5.5pmol/L). His thyroid pertechnetate uptake study
was diﬀusely uniform and increased to 9% (RR, 3–8%),
consistent with Graves’ disease (GD). His TSH Stimulating
Immunoglobulin (TSI) returned positive at 30IU/L (RR,
<10), his human TSH receptor antibody (hTRAB) was
15.8IU/L (RR, <2). His antithyroglobulin (Tg), (RR, < 1:
400), and antithyroperoxidase (TPO), (RR, < 1 : 400),
levels were undetectable. A diagnosis of GD was made but
the patient was reluctant to take medication as he was
well with excellent exercise tolerance and thus treatment
was withheld. Six weeks later, his fT3 level was 8.2pmol/L
and carbimazole was started. Three months later, he was
clinically well and his fT3 level has normalised. Treatment
was continued for 12 months during which his thyroid
function tests were normal. His follow-up TSI and hTRAB
antibodies had become undetectable at the end of treatment.2 International Journal of Endocrinology
1.2. Case 2. A 56-year-old woman presented with T3-
toxicosis 6 weeks following the completion of combination
RBVandIFN-α2βforherHCVinfection.Shehadundergone
antiviral therapy over the previous 48 weeks for her HCV
genotype 4 without any thyroid complications and had
achieved SVR. There was no previous personal or family
history of thyroid disease. As part of treatment protocols, her
monthly thyroid function tests for the duration of treatment
had been entirely normal. Four weeks after the completion
of therapy, she began to notice mild dyspnoea on exertion,
intermittent palpitation and heat intolerance. There were no
other symptoms of thyrotoxicosis. Clinically, she appeared
well with a regular pulse of 92bpm, BP of 130/80. No goitre
was detected nor were there any signs of thyrotoxicosis. Her
TSH was undetectable, fT4 was 24.1 and fT3 8.9pmol/L.
Her thyroid uptake scan was reduced at 2% (RR, 3–8). The
thyroid ultrasound was also normal in size and appearance;
there was no evidence of nodularity but mild increase
in vascularity. Her TSI, hTRAB, anti-Tg, and anti-TPO
antibodies were not detectable. One week later, her T3-
toxicosis persisted at 8.4pmol/L. A diagnosis of IFN-induced
thyroiditiswasmadeandlowdosepropanololwasprescribed
given her symptoms. She was followed closely with monthly
TSH, fT4, and fT3 levels. Eight weeks later, she had entered
into the hypothyroid phase with TSH of 54.6IU/L, fT4 8.8,
and fT3 2.3pmol/L. As the patient remained free of any
hypothyroid symptoms and given the expected recovery in
thyroiditides, thyroxine therapy was withheld. At 16 weeks,
herthyroidfunctionhadreturnedtonormal.Propanololwas
ceased and when last reviewed, the patient was in excellent
health with ongoing normal thyroid function tests.
1.3. Case 3. A 45-year-old woman presented for a routine
review 8 weeks following her failed therapy with IFN-α2β
for her chronic HCV. She had been generally well with no
signiﬁcant previous medical history although there was a
strong family history of thyroid disease in her family, with
both her mother and grandmother experiencing thyroid dis-
eases of undetermined nature, culminating in both requiring
thyroxine supplement. Treatment for her HCV infection
(genotype 1) was to be 48 weeks of RBV and IFN-α2β.
However, after 24 weeks, there was no reduction in viral
load and treatment was terminated. Her monthly thyroid
function tests had been normal till then. System review on
this occasion did not reveal any symptoms to suggest thyroid
disease. Clinical examination at the review visit showed no
signs of hypothyroidism. Her vital signs were satisfactory,
with normal tendon reﬂexes and no goitre. Her routine TSH
was found to be 48.0IU/L with undetectable fT4 level. The
follow-upthyroidultrasoundrevealedthepresenceofasmall
atrophic gland with total volume of 6mls (RR, 6–10) [1].
Her anti-Tg and anti-TPO titres were 1 : 256 and 1 : 512,
respectively. The TSI and hTRAB were 11IU/L and 11.7IU/L
respectively. Her thyroid uptake study was low at 3%. A diag-
nosis of autoimmune hypothyroidism was made and conse-
quently,thyroxinewasstarted.Shewasstabilisedon100μgof
thyroxine daily. At six month review, her anti-Tg, anti-TPO,
TSI and hTRAB antibodies were undetectable. In retrospect,
thecombinationofhighTSIandhTRABtitreswithhypothy-
roidism and a low pertechnetate uptake study was consistent
with the presence of thyrotropin blocking antibodies (TB-
Ab). Based on this probable underlying mechanism for
the hypothyroidism, thyroxine was ceased. The patient
remained well and independent of thyroxine supplement in
the following 12 months. Interferon-induced thyroiditis (in
the hypothyroid phase) was unlikely given that there was
no hyperthyroid phase. Functional TB-Ab assay would have
been deﬁnitive but unfortunately was not available.
The clinical proﬁles of the three cases are represented
schematically in Figure 1.
2. Discussion
The cases highlight the peculiar and fascinating spectrum
of thyroid disease in the ensuing months following the
completionofIFN-basedtherapyforchronicHCVinfection.
Our series demonstrates a wide spectrum of autoimmune
thyroid diseases, ranging from GD to thyroiditis to pro-
found subclinical hypothyroidism following IFN treatment.
In case 1, the pattern includes GD following thyroiditis
that occurred during the treatment phase. This unusual
occurrence, referred to as “tri-phasic”, has been reported
only once previously [2]. The predominance of T3 activity
was also peculiar, without progressing to ﬂorid GD. In
case 2, T3 thyroiditis occurred; this has not been described
previously nor has it been described in this particular clinical
setting. The clinical and biochemical behaviour is not very
diﬀerent from those arising de novo, expressing the classical
biphasic response despite the negative antibody ﬁndings.
Case 3 illustrates a complex mechanism of developing
hypothyroidism in, presumably, a pre-existing abnormal
thyroid gland. Despite normal TSH levels throughout the
treatment duration, the development and resolution of
hTRAB suggested the presence of TSH blocking antibody
(TB-Ab) to account for the hypothyroidism, although this
was never conclusively proven. The latter resolved, possibly
following TBAB disappearance after the IFN eﬀects had
waned. In all 3 cases, no baseline antibody proﬁles were
performed as they did not alter clinical management and
thyroid status was monitored monthly during therapy.
There are only two previous studies documenting the
long-term outcome of thyroid diseases but with IFN-α
monotherapy, rather than combination therapy. Carella et
al. [3] followed 114 patients for 6.2 years on average and
did not ﬁnd any overt thyroid dysfunction, only subclinical
hypothyroidism in 12 cases at the end of therapy and 7
cases at the end of followup. Doi et al. [4] followed 17
patients to an average of 71 months in which there were
9 hyper- and 8 hypothyroid cases. No overt thyroiditis was
observed, contrary to our current series. Tong et al. [5]
studied the eﬃcacy of consensus-IFN versus IFN-α (both in
combination with RBV). This study included a follow-up
period of 24 weeks posttreatment to coincide with the SVR
review. Although both hypothyroidism and hyperthyroidism
were included, no speciﬁc mention was made of their timing
or characteristics.
Thepathogenesisofthisconditionisinessenceunknown
but is probably distinct from the thyroid diseases arisingInternational Journal of Endocrinology 3
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Figure 1: Schematic summaries of the cases and their ﬁnal thyroid outcomes. The arrow bars indicate the duration of combination therapy
with interferon-α and ribavirin. See text for detailed discussions.
during the course of IFN therapy [6, 7] .C l e a r l y ,ac o m m o n
denominator is recent exposure to IFN therapy for chronic
HCV infection but it also clear that the process must have
been perpetuated by additional factors. This persistence of
theimmunereactionupto12monthsaftertherapyhadbeen
observed previously in 3 patients [8]. All of these individuals
achieved sustained virological response (SVR) whereas only
1 of our 3 cases did not. The exogenous IFN-α is believed to
stimulate lymphocyte, macrophage and neutrophil function
aswellasincreasingcytokineandchemokineconcentrations,
especially, interleukin-6 (IL-6) [8]. IFN-α induces MHC-
II expression and probably CD40 expression on thyrocytes
[9]. The latter results in an increased T-cell activation of
the CD40 signalling pathway within the thyroid gland.
This leads to an overexpression of intrathyroidal IL-6,
synergising with pre-existing and circulating IL-6, in turn
induces the development of thyroiditis. The high IL-6 is
also thought to block TSH-mediated iodine uptake leading
to the absent uptake scan [10]. Beside MHC-II, IFN also
induces MHC-I expression on thyrocytes by way of IL-2 and
chemokines [11], adding to the inﬂammatory response and
the thyroiditis. IFN is also known to have a direct toxic eﬀect
on thyrocytes [10]. Furthermore, HCV particles have been
found inside the thyrocytes [12] which could trigger and
sustain an intracellular T-cell response and inﬂammation
but this is unlikely assuming that there are no remaining
intrathyroidal HCV particles in the presence of SVR. All
these mechanisms are further ampliﬁed, exacerbated and
maintained by the exogenous IFN-α therapy [13].
Of recent interest is the function and place of regulatory
T-cells (Treg) in HCV infection and IFN-associated thyroidi-
tis. In HCV, the frequency of Treg is high which directly
suppresses T-cell overall function allowing the infection
to persist [14]. In animal models, Treg depletion induced
lymphocytic inﬁltration of the thyroid leading to transient
and/or permanent hypothyroidism [15]. Treatment with
interferon-β in patients with multiple sclerosis results in an
increased Treg inhibitory capacity leading to the favourable
outcome [16]. However, it is not known if this is the case
for IFN-α. Furthermore, for the T-cell immunity to elicit
the various immune thyroid disease, Treg response should
be dampened rather than enhanced to removs its inhibitory
capacity and allow the T-cell helpers (TH) to initiate the
autoimmunity process.
The discussed immune mechanism above is thought to
be under the auspices of the TH1 response. In GD, IFN
is thought to induce or modulate switching of the T-cell
response to TH2. This, in turn, stimulates B cell proliferation
and diﬀerentiation under the inﬂuence of IL-6 and increased
CD40 overexpression, resulting in an increase in TSI, sim-
ulating GD [9]. However, Nagayama et al. [17]s u g g e s t e d
additionallythatTH1initselfmightbeapotentialpathogenic
mechanism in GD. Similarly, the apparent hypothyroidism is
thought to be elicited by a similar mechanism but involving
the alternative TB-Ab. There is no apparent reason to
explain why the induced antibodies should be preferentially
be stimulating, inhibitory, neutral or even a mixture. The
pathogenesis is highly IFN dependent and resolves once4 International Journal of Endocrinology
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Figure 2: The proposed hypotheses for the development of the full spectrum of thyroid diseases after the completion of combination IFN-
based therapy. IL-6: Interleukin-6; IFN: Interferon; MHC-II: major histocompatability complex-II; GD: Graves’ disease; TH: T helper.
the prolonged IFN eﬀect has waned. This represents a
potentiallyreversiblepathwayforhypothyroidismotherthan
the hypothyroid phase of thyroiditis previously described
[18].Thecomplexpathogenesisofthisconditionascurrently
understood has been summarised in Figure 2.
It is well documented that hepatitis C infection is
associated with an increase in endocrinopathies, especially
autoimmune thyroid diseases, prior to and during therapy
[7, 19], with a prevalence of 7–19% [20] depending on
the studied population. Previous reports suggested that IFN
therapyandfemalegendercontributetodiseaserisk[20,21].
Our previous published data suggested that thyroid surveil-
lance is carried out monthly during treatment [7], although
the frequency of surveillance remains contentious and the
National Academy of Biochemistry is yet to recommend
thyroid testing in this clinical scenario [22]. Three monthly
TSH as suggested by Mandac et al. [19] may miss the entire
diagnosis as thyroid functions have completely normalized
in many cases. Both the British Society of Gastroenterology
and the American Gastroenterological Association recognise
the potential thyroid eﬀect of IFN and recommend thyroid
screening [23, 24]. However, only the former speciﬁes that
thyroid function testing is recommended at each treatment
visit, rather than monthly. The National Institute of Health
consensus statement on hepatitis C management surpris-
ingly did not address this issue [25].
To add to the complexity of the issue, it remains
unknown if thyroid diseases are increased post-IFN therapy
andiffemalegenderisariskfactor,especiallyoncethishighly
immunostimulatory virus has been eradicated. This is the
ﬁrst case series to explore the wide but probably incomplete
spectrum of autoimmune thyroid dysfunction immediately
following the completion of IFN-based treatment. This case
series is small and the development of thyroid disease may
arguably be incidental. However, the observation strongly
suggests a persisting and disrupted immune system. These
cases highlight the need for ongoing suspicion of thyroid
disease and probable thyroid surveillance strategy, at least
during the immediate 6–12 weeks following therapy comple-
tion and perhaps extending it to coincide with the time of
SVR review at 6 months posttherapy followup.
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